FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

UK Banks Strengthen Cybersecurity with Anthropics Mythos Model

New collaboration enhances banks' defense against cyber threats.Highlights: UK banks to access Anthropics Mythos model in the upcoming...
FinTech

UK Banks to Gain Access to Anthropic Cybersecurity Model Next Week

New collaboration enhances cybersecurity for UK banking institutions.Highlights: UK banks set to access Anthropic's cybersecurity model soon.Collaboration aims...
FinTech

ABN AMRO Expands Access to Crypto Investments

The bank now offers clients direct access to cryptocurrency.Highlights: ABN AMRO now allows clients to invest in cryptocurrency...
FinTech

UniCredit Strengthens Investment in Blockinvest with $4 Million Funding

The Italian bank targets innovation in blockchain technology through this investment.Highlights: UniCredit invests $4 million in Blockinvest to...